Welcome

World Pharma News is an ambitious online news service dedicated to the world pharmaceutical industry. Our main goal is to keep our readers informed about the latest worldwide pharmaceutical news, realizations and achievements.

Register now to be in touch with our last developments and achievements or Subscribe to World Pharma News alerts by Email (a free e-mail delivery powered by Google). Syndicated Content Powered by Google

Non progredi est regredi.

PharmaNews.eu PharmaNews.eu, an advanced web based news project, targeting the European pharmaceutical domain, has been launched. The project was developed to directly connect, promote and disseminate the European pharmaceutical achievements...
For further information, please visit http://www.pharmanews.eu

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

Sponsored Ads

Pharmaceutical RSS News

Start your day with worldwide pharmaceutical RSS news
[ Amgen | AstraZeneca | Boehringer Ingelheim | Bristol-Myers Squibb | GlaxoSmithKline | Janssen-Cilag | Johnson & Johnson | Novartis | Novo Nordisk | Pfizer | Roche | Shire | Takeda ]
European Commission European Commission - Pharmaceuticals
FDA US Food and Drug Administration
Google Groups
Get all news digests delivered to your inbox, subscribe to World Pharma News Google Group.
Email:

World Pharma News .net / Published News

Sponsored Ads

EMEA recommendation on use of angiotensin II receptor antagonists during pregnancy Print E-mail
Friday, 25 April 2008
The European Medicines Agency (EMEA)The European Medicines Agency (EMEA) has recommended that the product information of all centrally authorised angiotensin II receptor antagonists be harmonised, regarding their use during pregnancy. Following a review of the safety of these medicines during pregnancy, the EMEA's Committee for Medicinal Products for Human Use (CHMP), at its April 2008 meeting, recommended that the product information should state that the use of angiotensin II receptor antagonists should be avoided in the first three months of pregnancy.

The CHMP also confirmed that angiotensin II receptor antagonists must not be used during the second and the third trimester of pregnancy and that the contraindication already in place should therefore be maintained.

Angiotensin II receptor antagonists are used in the treatment of patients with essential hypertension (high blood pressure that has no identifiable cause).

The CHMP conclusions stem from a safety review conducted by the EMEA's Pharmacovigilance Working Party. This review included also a large number of non-centrally authorised medicines. Implementation of the recommendations for non-centrally authorised medicines will follow through the appropriate national procedures.

For more information, visit:
http://www.emea.europa.eu


Bookmark with:
Digg!Reddit!Del.icio.us!Google!Live!Facebook!Slashdot!Netscape!Technorati!StumbleUpon!Spurl!Newsvine!Furl!Yahoo!
 
< Prev   Next >
[ Back ]
Submit to World Pharma News .net

Most Read - Product

Sponsored Ads

Advertisement